Compile Data Set for Download or QSAR
Report error Found 209 Enz. Inhib. hit(s) with all data for entry = 2350
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM50004053(CHEMBL2180006 | US9834564, Compound 1 | US10562916...)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362429(US9834564, Compound 2 | US10562916, Compound 2)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362430(US9834564, Compound 3 | US10562916, Compound 14)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362431(US9834564, Compound 4 | US10562916, Compound 4)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362432(US9834564, Compound 5 | US10562916, Compound 5)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362444(US9834564, Compound 11 | US10562916, Compound 11)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362445(US9834564, Compound 12)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362446(US9834564, Compound 13 | US10562916, Compound 13)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362456(US9834564, Compound 16 | US10562916, Compound 16)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362457(US9834564, Compound 17 | US10562916, Compound 17)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362458(US9834564, Compound 18 | US10562916, Compound 18)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362459(US9834564, Compound 19 | US10562916, Compound 19)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362460(US9834564, Compound 20 | US10562916, Compound 20 |...)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362474(US9834564, Compound 34 | US10562916, Compound 34)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362476(US9834564, Compound 36 | US10562916, Compound 36)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362479(US9834564, Compound 39 | US10562916, Compound 39)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362480(US9834564, Compound 40 | US10562916, Compound 40)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362482(US9834564, Compound 42 | US10562916, Compound 42)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362483(US9834564, Compound 43 | US10562916, Compound 43)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362485(US9834564, Compound 45 | US10562916, Compound 45)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362486(US9834564, Compound 46 | US10562916, Compound 46)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362488(US9834564, Compound 48 | US10562916, Compound 48)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362489(US9834564, Compound 49 | US10562916, Compound 49)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362490(US9834564, Compound 50 | US10562916, Compound 50)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362491(US9834564, Compound 51 | US10562916, Compound 51)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362492(US9834564, Compound 52 | US10562916, Compound 52)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362496(US9834564, Compound 56 | US10562916, Compound 56)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362499(US9834564, Compound 59 | US10562916, Compound 59)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362501(US9834564, Compound 61 | US10562916, Compound 61)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM50003989(CHEMBL2180007 | US9834564, Compound 64 | US1056291...)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362507(US9834564, Compound 67 | US10562916, Compound 67)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362509(US9834564, Compound 69 | US10562916, Compound 69)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362510(US9834564, Compound 70 | US10562916, Compound 70)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362512(US9834564, Compound 72 | US10562916, Compound 72)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362513(US9834564, Compound 73 | US10562916, Compound 73)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362515(US9834564, Compound 75 | US10562916, Compound 75)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362516(US9834564, Compound 76 | US10562916, Compound 76)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362517(US9834564, Compound 77 | US10562916, Compound 77)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362518(US9834564, Compound 78 | US10562916, Compound 78)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362524(US9834564, Compound 84 | US10562916, Compound 84)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362525(US9834564, Compound 85 | US10562916, Compound 85)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362526(US9834564, Compound 86 | US10562916, Compound 86)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362527(US9834564, Compound 87 | US10562916, Compound 87)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362528(US9834564, Compound 88 | US10562916, Compound 88)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362529(US9834564, Compound 89 | US10562916, Compound 89)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362530(US9834564, Compound 90 | US10562916, Compound 90)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362532(US9834564, Compound 92 | US10562916, Compound 92)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362534(US9834564, Compound 94 | US10562916, Compound 94)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362542(US9834564, Compound 102 | US10562916, Compound 102)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM362543(US9834564, Compound 103 | US10562916, Compound 103)
Affinity DataIC50: 500nMAssay Description:The activities of the compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 e...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 209 total ) | Next | Last >>
Jump to: